Date: Oct 12, 2021

View Recorded Q&A

Read Additional Q&A from Dr. Tree

Define the current best practice for prostate Stereotactic Body Radiation Therapy (SBRT). Describe the evidence underpinning prostate SBRT practice. Discuss the recently released data from the international PACE-B trial, which randomized patients between standard fractionation radiotherapy and five fraction SBRT. 

Dr. Tree

Alison Tree, Consultant Clinical Oncologist MBBS, BSc, FRCR, M.D.(Res), Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London

Dr. Alison Tree was appointed as a consultant clinical oncologist at The Royal Marsden NHS Foundation Trust in 2014, specializing in urological malignancies. Her MD thesis was on stereotactic body radiotherapy (SBRT) techniques for prostate and oligometastatic cancer.
Her current research interests focus on technical radiotherapy developments in prostate cancer, aiming to make radiotherapy more effective and reduce side effects. Dr. Tree leads the Prostate Group in the International MR Linac consortium. She is currently leading trials in MR-guided prostate radiotherapy (the PRISM trial), boosting dominant intra-prostatic lesions (the DELINEATE trial) and ablating oligoprogressing metastases in advanced prostate cancer (the TRAP trial). She will soon be starting the HERMES trial which is testing whether prostate cancer can be cured in just 2 fractions.

Dr. O'Sullivan

Moderated by: Professor Joe O’Sullivan, M.D., FRCPI, FFRRCSI, FRCR, Queen’s University Belfast and Consultant Clinical Oncologist, Northern Ireland Cancer Center

Joe O’Sullivan is Professor of Radiation Oncology at the Center for Cancer Research and Cell Biology, Queen’s University Belfast and a Prostate Cancer Oncologist at the Northern Ireland Cancer Center, Belfast.

Professor O'Sullivan graduated from University College Dublin medical School in 1993 and trained in Radiation Oncology in St. Luke’s Hospital in Dublin. In 2000 he took up a Clinical research Fellowship at the Royal Marsden London, completing a Doctorate Thesis on the use of high doses of Rhenium-186HEDP with stem cell support in advanced prostate cancer. He was appointed as a senior lecturer and consultant clinical oncologist at Queen’s University Belfast in 2004 and was subsequently appointed as Professor of Radiation Oncology in 2011. He served as Clinical Director of Oncology at The Northern Ireland Cancer Center, Belfast from 2014 to 2017.

His research interests include radionuclide therapy in metastatic prostate cancer, translational research in prostate cancer and radiotherapy, and clinical trials in advanced prostate cancer and he has published over 200 research papers. He is one of the 4 Directors of the FASTMAN Prostate Cancer Center of Excellence (Belfast and Manchester) which is a program of research awarded in 2014 and funded by Movember and PCUK. 

Professor O'Sullivan is also a singer/songwriter and has released 3 albums of original songs, many inspired by his patients.